Abstract 40P
Background
Recent evidence suggests that breast cancer may have population-specific characteristics, including differences in the tumour immune microenvironment (TME). Immune cell markers in the TME, particularly CD8, may have utility as predictive and prognostic biomarkers, but there is conflicting evidence from previous studies. The aim of this study was to determine the prognostic utility of immune cell immunohistochemistry markers in tumor samples from a cohort of breast cancer patients from Malaysia.
Methods
We obtained digitized whole slide images of breast tumour tissue samples stained for CD3, CD4, CD8, and PD-L1 markers for 576 breast cancer patients from Subang Jaya Medical Centre, a Malaysian private hospital. These patients were included in the Malaysian Breast Cancer (MyBrCa) study cohort, and thus multi-omics data were also available for analysis for each patient. We also obtained overall survival data from the Malaysian national registry for this group of patients, with a median follow-up time of 68 months.
Results
We compared the intra-tumoral scores for each marker to overall survival data and found that the scores for CD3, CD4, and CD8, but not PD-L1, were positively associated with overall survival, particularly for patients with triple-negative breast cancer (TNBC). Additionally, the CD3, CD4, and CD8 scores were not associated with tumour mutational burden (TMB) or neoantigen load and had a negative correlation with copy number aberrations.
Conclusions
Our results suggest that intra-tumoral markers for T-cells are indicative of good prognosis in Asian breast cancer. Our results also suggest that the TME in Asian breast cancer may be shaped by non-canonical pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Cancer Research Malaysia, Yayasan PETRONAS, Yayasan Sime Darby, Scientex Foundation, Estee Lauder Companies, Vistage Malaysia, Newton-Ungku Omar Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract